Trikafta is a prescription medication used to treat cystic fibrosis (CF), a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to impaired chloride transport, thick mucus accumulation, and progressive damage to the lungs, pancreas, and other organs. Trikafta combines elexacaftor and tezacaftor (correctors that improve CFTR protein folding and trafficking to the cell surface) with ivacaftor (a potentiator that enhances CFTR channel function), targeting mutations like F508del and others responsive to this therapy. It is approved for patients aged 2 years and older with eligible mutations, improving lung function, reducing pulmonary exacerbations, and enhancing overall quality of life.
The development of Trikafta and related CFTR modulators involved significant investment from the Cystic Fibrosis Foundation (CFF), which provided approximately $150 million to Vertex Pharmaceuticals between the late 1990s and early 2010s to support research and clinical trials. In return, the CFF received royalty rights on sales of these therapies. In 2014, the CFF sold these royalty rights for $3.3 billion to Royalty Pharma, generating substantial funds to advance CF research, care programs, and therapeutic development. In 2020, the CFF sold its remaining royalty stake for an upfront payment of $575 million, with a potential additional $75 million, further bolstering resources for the CF community.
In late 2024, the U.S. Food and Drug Administration (FDA) updated Trikafta’s labeling to include a black box warning—the agency’s strongest safety alert—due to the risk of serious and potentially fatal drug-induced liver injury (DILI). Postmarketing surveillance and adverse event reports documented cases of liver failure requiring transplantation or resulting in death, occurring in patients both with and without pre-existing liver disease, including those with cirrhosis or portal hypertension. These events prompted the elevation of prior precautions to a boxed warning. The prescribing information now states that liver failure leading to transplantation and death has been reported, and advises avoiding Trikafta in patients with advanced liver disease unless benefits clearly outweigh risks. Monitoring includes liver function tests (e.g., ALT, AST, alkaline phosphatase, bilirubin) before initiation, monthly for the first 6 months, every 3 months for the following year, and annually thereafter, with more frequent checks for at-risk patients. Treatment interruption is recommended for significant elevations (e.g., ALT/AST >5× upper limit of normal, or >3× with elevated bilirubin) or signs/symptoms of liver injury, potentially with hepatologist referral.
One notable case highlighting these risks involves Joy Zuraff and her daughter Kenlee, who has cystic fibrosis. In early 2024, a dispute arose over initiating Trikafta for Kenlee, with Zuraff expressing concerns about potential side effects, including liver-related risks noted in the drug’s safety profile at the time. This led to allegations of medical neglect, resulting in the child’s removal by Florida’s Department of Children and Families (DCF) on March 6, 2024. Zuraff maintained she was not refusing all treatment but sought more data, a second opinion, or delayed introduction due to safety considerations. Subsequent developments included the FDA’s addition of the black box warning in December 2024, which some advocates cited as validating concerns about severe hepatic risks. The case has involved ongoing legal proceedings, including reports of elevated liver enzymes in the child during foster care and debates over parental rights in medical decision-making.
The Cystic Fibrosis Foundation plays a central role in establishing recommendations and standards of care for CF clinics across the United States. The CFF accredits specialized CF care centers, requiring them to adhere to evidence-based clinical practice guidelines and consensus statements developed by the foundation. These guidelines, created by multidisciplinary committees of experts, cover aspects such as diagnosis, treatment protocols, infection control, nutritional management, and pulmonary care, ensuring a standardized approach to CF management. Accreditation involves annual reviews and site visits to verify compliance, promoting consistent high-quality care delivery. The guidelines are informed by the latest research, clinical data, and expert consensus, and they influence care models at accredited centers, including multidisciplinary team composition and routine monitoring practices.
Black box warnings serve as a critical regulatory mechanism by the FDA to highlight serious or life-threatening risks that could affect prescribing, patient selection, or monitoring. They are based on evidence from clinical trials, post-approval data, or real-world reports indicating hazards that warrant prominent attention. For Trikafta, the warning arose from accumulating postmarketing evidence of DILI severity, ensuring clinicians weigh benefits against risks, implement vigilant monitoring, and inform patients fully. This promotes safer use of high-impact therapies while advancing CF treatment.
In summary, Trikafta’s black box warning reflects documented risks of severe liver injury, including rare fatal outcomes or transplantation needs, as seen in postmarketing cases. The Joy Zuraff case illustrates how such risks can intersect with clinical and legal considerations in CF management, while the Cystic Fibrosis Foundation’s substantial returns from its investments in CFTR modulators have funded ongoing advancements, and its guidelines set the benchmark for standardized care at CF clinics. This underscores the importance of informed, individualized decisions and rigorous monitoring in pharmacology.
Official FDA and Prescribing Information
- U.S. FDA Prescribing Information for TRIKAFTA (updated label with boxed warning): https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212273s013lbl.pdf (Details the boxed warning for drug-induced liver injury and liver failure, including postmarketing reports of transplantation and death.)
- Vertex Pharmaceuticals announcement on FDA approval and label update (December 20, 2024): https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-trikafta (Confirms the elevation to boxed warning for liver injury/failure risks.)
- TRIKAFTA Important Safety Information (patient-facing, from Vertex): https://www.trikafta.com/important-safety-information (Describes liver failure cases and monitoring recommendations.)
Joy Zuraff and Kenlee Case
- Santa Rosa Press Gazette article on the case (local reporting on removal and dispute): https://srpressgazette.com/taken-in-minutes-a-local-case-spotlighting-floridas-child-welfare-system
- Florida Voice News coverage of allegations of medical kidnapping and treatment dispute: https://flvoicenews.com/florida-mother-alleges-dcf-medically-kidnapped-her-child-with-cystic-fibrosis-after-she-questioned-risky-drugs
Cystic Fibrosis Foundation Investments and Royalties
- Cystic Fibrosis Foundation statement on venture philanthropy and royalty sales: https://www.cff.org/about-us/our-venture-philanthropy-model (Details $150 million invested in Vertex, $3.3 billion royalty sale to Royalty Pharma in 2014, and additional $575 million + $75 million potential in 2020.)
*Article currently not visible. - Royalty Pharma announcement on acquiring residual royalty interest (November 2020): https://www.royaltypharma.com/news/royalty-pharma-acquires-additional-royalty-interest-cystic (Confirms upfront $575 million payment and elimination of prior revenue thresholds.)
- CFF press release on 2014 royalty sale: https://www.cff.org/press-releases/2014-11/cystic-fibrosis-foundation-royalty-sale-will-be-transformational-people-cf (Announces $3.3 billion transaction to fund research, care, and programs.)
- Deal by Cystic Fibrosis Foundation Raises Cash and Some Concern
New York Times Archive https://web.archive.org/web/20190330093715/https://www.nytimes.com/2014/11/19/business/for-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html
Cystic Fibrosis Foundation Role in Guidelines and Accreditation
- CFF Clinical Care Guidelines overview: https://www.cff.org/medical-professionals/clinical-care-guidelines(Explains development of evidence-based guidelines for accredited centers.)
- CFF explanation of guideline development process: https://www.cff.org/medical-professionals/how-are-cf-clinical-care-guidelines-developed (Describes expert committees and standardization for CF care.)
- CFF Care Center Accreditation terms: https://www.cff.org/sites/default/files/2022-03/Care-Center-Award-Terms-and-Conditions.pdf (Outlines requirements for accreditation, compliance with guidelines, and annual reviews.)
